Cell Robotics Launches International Diabetic Laser Sales With FDA and CE Mark Approvals.

Business Editors & Health Care Industry Writers

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--July 17, 2000

- European Certification (CE Mark) has been granted for the Lasette - Nutech International Ltd. to distribute Lasette in U.K. - Ming-Mei Technology Company Ltd. to distribute Lasette in Taiwan

Cell Robotics International, Inc. (OTC:CRII), a manufacturer and marketer of medical and scientific laser devices, today announced that it has received European Certification (CE Mark) for the Personal Lasette(R). The award-winning Lasette technology is the only U.S. FDA cleared alternative to the steel lancet for drawing capillary blood. The Personal Lasette is a miniature laser finger perforator, slightly larger than a cell phone, that allows diabetics to draw blood to test blood glucose levels with minimal pain, no residual soreness and eliminates the cause of needle phobia. Detailed information about purchasing the Lasette and media quality photos can be found at www.cellrobotics.com. Interested distributors should submit form http://www.cellrobotics.com/DIS_Form.html or send e-mail to [e-mail].

The award of the CE Mark, the previously granted ISO 9001 and EN46001 certifications, ensures that Cell Robotics' products meet the quality and safety standards accepted by over 100 countries, including all of Europe, Brazil, Argentina, Australia, New Zealand and South Korea. This allows Cell Robotics to immediately sell Lasettes in all countries recognizing either the CE or FDA standard.

U.K. and Taiwan Distributors

With the CE Mark in place, the first European distributor to be announced is Nutech International Ltd., which specializes in sales and marketing within the United Kingdom of medical instruments of high quality that carry the CE Mark and have FDA clearance. Nutech is an approved supplier to the U.K. health service and the U.K. Ministry of Defense. Nutech's Managing Director and CEO, J. C. Boden, is an insulin-dependent diabetic who sits on many important committees concerning diabetes, including the World Health Organization.

The second international distributor is Ming-Mei Technology Company, Ltd. of Taiwan. Ming-Mei has 40 sales people to sell both medical and other products in Taiwan. Ming-Mei will sell the Lasette in cooperation with major diabetic centers and through service clubs with TV promotions. President Arthur Hsieh is an advocate for improving the quality of life for the people of Taiwan who live with diabetes.

Diabetes is a chronic disease that currently has no cure and is a leading cause of death worldwide. The International Diabetes Institute provides the following numbers of people with diabetes by region: 16.9 million in North America, 23.7 million in Europe, 51.2 million in Asia and 12.6 million in Latin America.

As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; and the risks described from time to time in the Company's Securities and Exchange Commission filings.